Related Experiment Video
Updated: May 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells
Mohsan Saeed1, Troels K H Scheel, Judith M Gottwein
1Laboratory of Virology and Infectious Diseases, Center for the Study of Hepatitis C, The Rockefeller University, New York, New York, USA.
Abstract:
Despite recent advances in the treatment of hepatitis C, the quest for pan-genotype, effective, and well-tolerated inhibitors continues. To facilitate these efforts, it is desirable to have in vitro replication systems for all major HCV genotypes. However, cell culture replication systems exist for only genotypes 1a, 1b, and 2a. In this study, we generated G418-selectable subgenomic replicons for prototype strains of genotypes 3a (S52) and 4a (ED43). Production of G418-resistant colonies by S52 and ED43 in Huh-7.5 cells required the amino acid substitutions S2210I and R2882G, respectively, cell culture adaptive mutations originally reported for genotype 1b replicons. RNA replication was confirmed by quantitative reverse transcription-PCR and detection of viral protein. Sequencing of multiple independent replicon clones revealed the presence of additional nonsynonymous mutations. Interestingly, all potentially adaptive mutations mapped to the NS3 protein. These mutations, when introduced back into original constructs, substantially increased colony formation efficiency. To make these replicons useful for high-throughput screening and evaluation of antiviral compounds, they were modified to express a chimeric fusion protein of firefly luciferase and neomycin phosphotransferase to yield stable replicon-expressing cells. Using these constructs, the inhibitory effects of beta interferon (IFN-β), an NS3 protease inhibitor, and an NS5B nucleoside polymerase inhibitor were readily detected by monitoring luciferase activity. In conclusion, we have established functional replicons for HCV genotypes 3a and 4a, important new additions to the armamentarium required to develop inhibitors with a pan-genotype activity.
Insights
Researchers developed new cell culture systems for hepatitis C virus (HCV) genotypes 3a and 4a. These functional replicons are crucial for discovering pan-genotype HCV inhibitors and advancing antiviral therapies.
Area of Science:
- Virology
- Hepatology
- Drug Discovery
Background:
- Hepatitis C virus (HCV) treatment advances continue, yet pan-genotype inhibitors are needed.
- Existing in vitro replication systems are limited to HCV genotypes 1a, 1b, and 2a.
- Developing systems for other genotypes is essential for comprehensive antiviral research.
Purpose of the Study:
- To establish functional in vitro replication systems for Hepatitis C virus (HCV) genotypes 3a and 4a.
- To facilitate the development of pan-genotype HCV inhibitors.
- To enable high-throughput screening of antiviral compounds against diverse HCV strains.
Main Methods:
- Generated G418-selectable subgenomic replicons for HCV genotypes 3a (S52) and 4a (ED43).
- Identified and incorporated cell culture adaptive mutations (S2210I and R2882G) in NS3 protein.
- Modified replicons to express firefly luciferase-neomycin phosphotransferase fusion protein for stable cell lines.
Main Results:
- Successfully established functional replicons for HCV genotypes 3a and 4a in Huh-7.5 cells.
- Confirmed RNA replication and viral protein expression.
- Demonstrated detection of antiviral compound inhibition (IFN-β, NS3 protease inhibitor, NS5B polymerase inhibitor) via luciferase activity.
Conclusions:
- Established functional replicons for HCV genotypes 3a and 4a, expanding the available research tools.
- These replicons are valuable for evaluating inhibitors against a broader range of HCV genotypes.
- This work contributes to the development of pan-genotype HCV antiviral therapies.
Related Concept Videos
Hepatitis
Viruses with RNA Genomes

